WO1993001286A2 - Localized oligonucleotide therapy - Google Patents
Localized oligonucleotide therapy Download PDFInfo
- Publication number
- WO1993001286A2 WO1993001286A2 PCT/US1992/005305 US9205305W WO9301286A2 WO 1993001286 A2 WO1993001286 A2 WO 1993001286A2 US 9205305 W US9205305 W US 9205305W WO 9301286 A2 WO9301286 A2 WO 9301286A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotide
- oligonucleotides
- antisense
- myb
- tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5502240A JPH07501204A (en) | 1991-06-28 | 1992-06-23 | Topical oligonucleotide therapy |
AU23032/92A AU659482B2 (en) | 1991-06-28 | 1992-06-23 | Localized oligonucleotide therapy |
NO934828A NO934828L (en) | 1991-06-28 | 1993-12-27 | Localized oligonucleotide therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72345491A | 1991-06-28 | 1991-06-28 | |
US723,454 | 1991-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993001286A2 true WO1993001286A2 (en) | 1993-01-21 |
WO1993001286A3 WO1993001286A3 (en) | 1993-04-01 |
Family
ID=24906337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/005305 WO1993001286A2 (en) | 1991-06-28 | 1992-06-23 | Localized oligonucleotide therapy |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPH07501204A (en) |
AU (1) | AU659482B2 (en) |
WO (1) | WO1993001286A2 (en) |
Cited By (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2704556A1 (en) * | 1993-04-30 | 1994-11-04 | Rhone Poulenc Rorer Sa | Recombinant viruses and their use in gene therapy |
EP0653439A2 (en) * | 1993-11-12 | 1995-05-17 | Hoechst Aktiengesellschaft | Stabilized oligonucleotids and the use thereof |
EP0695170A1 (en) * | 1993-04-19 | 1996-02-07 | Medisorb Technologies International L.P. | Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles |
WO1996011266A2 (en) * | 1994-10-05 | 1996-04-18 | Amgen Inc. | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
US5605821A (en) * | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
US5683873A (en) * | 1995-01-13 | 1997-11-04 | Innovir Laboratories, Inc. | EGS-mediated inactivation of target RNA |
US5750351A (en) * | 1992-10-30 | 1998-05-12 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5821234A (en) * | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
WO1998046740A1 (en) * | 1997-04-17 | 1998-10-22 | Antivirals, Inc. | Method of treating restenosis by antisense targeting of cmv |
US5843884A (en) * | 1995-11-15 | 1998-12-01 | Oklahoma Medical Research Foundation | C9 complement inhibitor |
US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US5850002A (en) * | 1994-04-20 | 1998-12-15 | Washington University | Animal models for loss and gain of Hox11 function |
US5869462A (en) * | 1992-09-10 | 1999-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
US5869248A (en) * | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
US5877203A (en) * | 1992-10-30 | 1999-03-02 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5898066A (en) * | 1994-08-26 | 1999-04-27 | Children's Medical Center Corporation | Trophic factors for central nervous system regeneration |
US5925333A (en) * | 1995-11-15 | 1999-07-20 | Massachusetts Institute Of Technology | Methods for modulation of lipid uptake |
US5962322A (en) * | 1996-11-15 | 1999-10-05 | Massachusetts Institute Of Technology | Methods for modulation of cholesterol transport |
EP0950060A1 (en) * | 1996-12-02 | 1999-10-20 | Dyad Pharmaceutical Corporation | Antisense inhibition of human adhesion molecules |
US5985354A (en) * | 1995-06-07 | 1999-11-16 | Brown University Research Foundation | Preparation of multiwall polymeric microcapsules from hydrophilic polymers |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US6080727A (en) * | 1996-03-26 | 2000-06-27 | Istituto Regina Elena | Oligonucleotide treatments and compositions for human melanoma |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US6284729B1 (en) | 1996-11-06 | 2001-09-04 | Children's Medical Center Corporation | Methods and reagents for regulating obesity |
WO2002004479A1 (en) | 2000-07-06 | 2002-01-17 | Avi Biopharma, Inc. | TRANSFORMING GROWTH FACTOR BETA (TGF-β) BLOCKING AGENT-TREATED STEM CELL COMPOSITION AND METHOD |
US6350859B1 (en) | 1994-06-23 | 2002-02-26 | Massachusetts Institute Of Technology | Class BI and CI scavenger receptors |
US6395876B1 (en) | 1997-12-05 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
US6410508B1 (en) | 1998-10-07 | 2002-06-25 | Med College Georgia Res Inst | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
WO2005017148A1 (en) | 2003-07-26 | 2005-02-24 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7045350B2 (en) | 2001-08-30 | 2006-05-16 | Mount Sinai School Of Medicine Of New York University | Alternatively spliced circulating tissue factor |
US7166568B1 (en) | 1998-02-09 | 2007-01-23 | Oklahoma Medical Research Foundation | Compositions and methods to inhibit formation of the C5b-9 complex of complement |
US7208467B2 (en) | 2002-06-07 | 2007-04-24 | Monty Krieger | Lipid-altering compositions for the treatment of infertility |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
WO2009117553A2 (en) | 2008-03-20 | 2009-09-24 | University Of Florida Research Foundation, Inc. | Enhancing vessel lesion homing and repair potential of stem cells |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
WO2010062697A2 (en) | 2008-10-30 | 2010-06-03 | Peixuan Guo | Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses |
US7928216B2 (en) | 2004-04-29 | 2011-04-19 | Yale University | Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases |
EP2316951A1 (en) | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2011060320A1 (en) | 2009-11-13 | 2011-05-19 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7973015B2 (en) | 2000-09-21 | 2011-07-05 | Academisch Ziekenhuis Leiden | Induction of exon skipping in eukaryotic cells |
EP2351839A2 (en) | 2004-07-02 | 2011-08-03 | AVI BioPharma, Inc. | Antisense antibacterial method and compound |
WO2011113015A2 (en) | 2010-03-12 | 2011-09-15 | Avi Biopharma, Inc. | Antisense modulation of nuclear hormone receptors |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
WO2011150408A2 (en) | 2010-05-28 | 2011-12-01 | Avi Biopharma, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
US8084015B2 (en) | 2002-02-14 | 2011-12-27 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
WO2012021141A1 (en) | 2010-08-09 | 2012-02-16 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
WO2012064991A1 (en) | 2010-11-12 | 2012-05-18 | Avi Biopharma, Inc. | Antisense antibacterial compounds and methods |
US8263760B2 (en) | 2008-02-08 | 2012-09-11 | Prosensa Holding Bv | Methods and means for treating DNA repeat instability associated genetic disorders |
US8268962B2 (en) | 2007-07-12 | 2012-09-18 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
US8304398B2 (en) | 2006-04-20 | 2012-11-06 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly or abnormally expressed gene |
WO2012150960A1 (en) | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
WO2013012752A2 (en) | 2011-07-15 | 2013-01-24 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
US8361979B2 (en) | 2006-05-19 | 2013-01-29 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
US8436163B2 (en) | 2000-05-04 | 2013-05-07 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
WO2013082551A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
WO2013082548A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
WO2013086444A2 (en) | 2011-12-08 | 2013-06-13 | Sarepta Therapeutics, Inc. | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
WO2013134743A1 (en) | 2012-03-08 | 2013-09-12 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2013142087A1 (en) | 2012-03-20 | 2013-09-26 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
EP2735568A1 (en) | 2006-05-10 | 2014-05-28 | AVI BioPharma, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
WO2014165814A1 (en) | 2013-04-04 | 2014-10-09 | Georgia State University Research Foundation, Inc. | Rna microchip detection using nanoparticle-assisted signal amplification |
WO2015035231A1 (en) | 2013-09-05 | 2015-03-12 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
WO2015038984A2 (en) | 2013-09-12 | 2015-03-19 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
US9017679B2 (en) | 2005-08-30 | 2015-04-28 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US9045754B2 (en) | 2006-05-05 | 2015-06-02 | Isis Pharmaceuticals, Inc. | Short antisense compounds with gapmer configuration |
US9139828B2 (en) | 2008-05-14 | 2015-09-22 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means |
US9243245B2 (en) | 2007-10-26 | 2016-01-26 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
US9278987B2 (en) | 2011-11-18 | 2016-03-08 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
EP3023496A2 (en) | 2010-05-13 | 2016-05-25 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
US9499627B2 (en) | 2009-08-03 | 2016-11-22 | University Of Miami | Method for in vivo expansion of T regulatory cells |
WO2016196670A1 (en) | 2015-06-01 | 2016-12-08 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
US9603925B2 (en) | 2013-01-09 | 2017-03-28 | University Of Miami | Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use |
WO2017112888A1 (en) | 2015-12-23 | 2017-06-29 | David Greenberg | Antisense antibacterial compounds and methods |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
WO2017184529A1 (en) | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
WO2017190041A1 (en) | 2016-04-29 | 2017-11-02 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
US9890379B2 (en) | 2006-08-11 | 2018-02-13 | Biomarin Technologies B.V. | Treatment of genetic disorders associated with DNA repeat instability |
US9896687B2 (en) | 2003-03-21 | 2018-02-20 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US10179912B2 (en) | 2012-01-27 | 2019-01-15 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
US10391098B2 (en) | 2014-05-19 | 2019-08-27 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
US10421969B2 (en) | 2011-10-04 | 2019-09-24 | Royal Holloway And Bedford New College | Oligomers |
US10421967B2 (en) | 2014-05-15 | 2019-09-24 | Hoffmann-La Roche Inc. | Oligomers and oligomer conjugates |
US10533171B2 (en) | 2009-04-24 | 2020-01-14 | Biomarin Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
EP3626822A1 (en) | 2014-08-15 | 2020-03-25 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
US10626396B2 (en) | 2005-02-09 | 2020-04-21 | Sarepta Therapeutics, Inc. | Antisense composition and method for treating muscle atrophy |
US10907158B2 (en) | 2015-12-23 | 2021-02-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
US11015200B2 (en) | 2015-03-18 | 2021-05-25 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in myostatin |
EP3858993A1 (en) | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
WO2021163079A1 (en) | 2020-02-10 | 2021-08-19 | Biomarin Pharmaceutical Inc. | Virus-free cell cultures |
US11293024B2 (en) | 2014-12-31 | 2022-04-05 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
WO2022269016A1 (en) | 2021-06-25 | 2022-12-29 | Stichting Radboud Universitair Medisch Centrum | Allele-specific silencing therapy for dfna21 using antisense oligonucleotides |
US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
WO2023055774A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2024044770A1 (en) | 2022-08-26 | 2024-02-29 | Core Biotherapeutics, Inc. | Oligonucleotides for the treatment of breast cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU649734B2 (en) * | 1990-08-16 | 1994-06-02 | Isis Pharmaceuticals, Inc. | Inhibition of candida |
WO2024074670A1 (en) | 2022-10-06 | 2024-04-11 | Stichting Radboud Universitair Medisch Centrum | Antisense oligonucleotides for treatment of usher 2a. exon 68 |
WO2024074668A1 (en) | 2022-10-06 | 2024-04-11 | Stichting Radboud Universitair Medisch Centrum | Antisense oligonucleotides for treatment of usher 2a. exons 30-31 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1072413A (en) * | 1976-07-13 | 1980-02-26 | West Laboratories | Poloxamer gel systems with gelling temperatures higher than room temperature |
EP0248531A2 (en) * | 1986-05-02 | 1987-12-09 | Southern Research Institute | Encapsulated nucleic acids |
EP0326727A1 (en) * | 1986-10-10 | 1989-08-09 | International Minerals And Chemical Corporation | Sustained release implant and method for preparing same |
WO1990005445A1 (en) * | 1988-11-07 | 1990-05-31 | Temple University Of The Commonwealth System Of Higher Education | Antisense oligonucleotides to c-myb proto-oncogene and uses thereof |
EP0417572A2 (en) * | 1989-09-14 | 1991-03-20 | Massachusetts Institute Of Technology | Extended drug delivery of small, water-soluble molecules |
-
1992
- 1992-06-23 JP JP5502240A patent/JPH07501204A/en active Pending
- 1992-06-23 WO PCT/US1992/005305 patent/WO1993001286A2/en not_active Application Discontinuation
- 1992-06-23 AU AU23032/92A patent/AU659482B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1072413A (en) * | 1976-07-13 | 1980-02-26 | West Laboratories | Poloxamer gel systems with gelling temperatures higher than room temperature |
EP0248531A2 (en) * | 1986-05-02 | 1987-12-09 | Southern Research Institute | Encapsulated nucleic acids |
EP0326727A1 (en) * | 1986-10-10 | 1989-08-09 | International Minerals And Chemical Corporation | Sustained release implant and method for preparing same |
WO1990005445A1 (en) * | 1988-11-07 | 1990-05-31 | Temple University Of The Commonwealth System Of Higher Education | Antisense oligonucleotides to c-myb proto-oncogene and uses thereof |
EP0417572A2 (en) * | 1989-09-14 | 1991-03-20 | Massachusetts Institute Of Technology | Extended drug delivery of small, water-soluble molecules |
Non-Patent Citations (7)
Title |
---|
CIRCULATION RESEARCH vol. 70, no. 4, April 1992, pages 835 - 843 SIMONS, M. ET AL. 'Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro' * |
J.AM.COLL. CARDIOL.; Volume 19 (number 3, supplement A); 1 march 1992 page 165A; abstract number 759-6 PICKERING, G. ET AL.: proliferation of human vascular smooth muscle cells using antisense oligonucleotides to PCNA * |
JOURNAL OF BIOLOGICAL CHEMISTRY vol. 264, no. 12, 25 April 1989, BALTIMORE, MD US pages 6990 - 6995 REILLY, C.F. ET AL. 'Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle' cited in the application * |
JOURNAL OF BIOLOGICAL CHEMISTRY vol. 267, no. 7, 5 March 1992, BALTIMORE, MD US pages 4625 - 4630 BROWN, K.E. ET AL. 'Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cells' * |
JOURNAL OF THE NATIONAL CANCER INSTITUTE vol. 81, no. 20, 18 October 1989, pages 1539 - 1545 ROTHENBERG, M. ET AL. 'Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications' * |
NUCLEIC ACIDS RESEARCH vol. 19, no. 4, 25 February 1991, ARLINGTON, VIRGINIA US pages 747 - 750 SHAW, J.-P. ET AL. 'Modified deoxyoligonucleotides stable to exonuclease degradation in serum' cited in the application * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 86, May 1989, WASHINGTON US pages 3379 - 3383 ANFOSSI, G. ET AL. 'An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines' cited in the application * |
Cited By (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511749B1 (en) | 1987-05-01 | 2003-01-28 | Brown University Research Foundation | Preparation of multiwall polymeric microcapsules from hydrophilic polymers |
US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US5605821A (en) * | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
US5869462A (en) * | 1992-09-10 | 1999-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
US5821234A (en) * | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
US5811449A (en) * | 1992-10-30 | 1998-09-22 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5877203A (en) * | 1992-10-30 | 1999-03-02 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5846959A (en) * | 1992-10-30 | 1998-12-08 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5750351A (en) * | 1992-10-30 | 1998-05-12 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5773209A (en) * | 1992-10-30 | 1998-06-30 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5773231A (en) * | 1992-10-30 | 1998-06-30 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
EP0695170A1 (en) * | 1993-04-19 | 1996-02-07 | Medisorb Technologies International L.P. | Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles |
EP0695170A4 (en) * | 1993-04-19 | 1998-08-19 | Medisorb Technologies Internat | Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles |
FR2704556A1 (en) * | 1993-04-30 | 1994-11-04 | Rhone Poulenc Rorer Sa | Recombinant viruses and their use in gene therapy |
WO1994025073A1 (en) * | 1993-04-30 | 1994-11-10 | Rhone-Poulenc Rorer S.A. | Recombinant viruses and their use in gene therapy |
EP0653439A3 (en) * | 1993-11-12 | 1995-10-25 | Hoechst Ag | Stabilized oligonucleotids and the use thereof. |
EP0653439A2 (en) * | 1993-11-12 | 1995-05-17 | Hoechst Aktiengesellschaft | Stabilized oligonucleotids and the use thereof |
US6348312B1 (en) | 1993-11-12 | 2002-02-19 | Hoescht Aktiengesellschaft | Stabilized oligonucleotides and their use |
US5869248A (en) * | 1994-03-07 | 1999-02-09 | Yale University | Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences |
US5850002A (en) * | 1994-04-20 | 1998-12-15 | Washington University | Animal models for loss and gain of Hox11 function |
US7078511B1 (en) | 1994-06-23 | 2006-07-18 | Massachusette Institute Of Technology | Class BI and CI scavenger receptors |
US6350859B1 (en) | 1994-06-23 | 2002-02-26 | Massachusetts Institute Of Technology | Class BI and CI scavenger receptors |
US5898066A (en) * | 1994-08-26 | 1999-04-27 | Children's Medical Center Corporation | Trophic factors for central nervous system regeneration |
WO1996011266A2 (en) * | 1994-10-05 | 1996-04-18 | Amgen Inc. | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
WO1996011266A3 (en) * | 1994-10-05 | 1996-12-12 | Amgen Inc | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
US5683873A (en) * | 1995-01-13 | 1997-11-04 | Innovir Laboratories, Inc. | EGS-mediated inactivation of target RNA |
US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
US6528035B1 (en) | 1995-06-07 | 2003-03-04 | Brown University Research Foundation | Multiwall polymeric microcapsules from hydrophilic polymers |
US5985354A (en) * | 1995-06-07 | 1999-11-16 | Brown University Research Foundation | Preparation of multiwall polymeric microcapsules from hydrophilic polymers |
US6555525B2 (en) | 1995-08-31 | 2003-04-29 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US5925333A (en) * | 1995-11-15 | 1999-07-20 | Massachusetts Institute Of Technology | Methods for modulation of lipid uptake |
US5843884A (en) * | 1995-11-15 | 1998-12-01 | Oklahoma Medical Research Foundation | C9 complement inhibitor |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
US6080727A (en) * | 1996-03-26 | 2000-06-27 | Istituto Regina Elena | Oligonucleotide treatments and compositions for human melanoma |
US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
US6284729B1 (en) | 1996-11-06 | 2001-09-04 | Children's Medical Center Corporation | Methods and reagents for regulating obesity |
US5962322A (en) * | 1996-11-15 | 1999-10-05 | Massachusetts Institute Of Technology | Methods for modulation of cholesterol transport |
EP0950060A4 (en) * | 1996-12-02 | 2000-07-05 | Dyad Pharmaceutical Corp | Antisense inhibition of human adhesion molecules |
EP0950060A1 (en) * | 1996-12-02 | 1999-10-20 | Dyad Pharmaceutical Corporation | Antisense inhibition of human adhesion molecules |
WO1998046740A1 (en) * | 1997-04-17 | 1998-10-22 | Antivirals, Inc. | Method of treating restenosis by antisense targeting of cmv |
US7160539B2 (en) | 1997-12-05 | 2007-01-09 | Medical College Of Georgia | Regulation of T cell-mediated immunity by tryptophan |
US6482416B2 (en) | 1997-12-05 | 2002-11-19 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
US8198265B2 (en) | 1997-12-05 | 2012-06-12 | Medical College Of Georgia Research Institute Inc. | Regulation of T cell-mediated immunity by tryptophan |
US7879791B2 (en) | 1997-12-05 | 2011-02-01 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
US6395876B1 (en) | 1997-12-05 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
US7166568B1 (en) | 1998-02-09 | 2007-01-23 | Oklahoma Medical Research Foundation | Compositions and methods to inhibit formation of the C5b-9 complex of complement |
US6410508B1 (en) | 1998-10-07 | 2002-06-25 | Med College Georgia Res Inst | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US9416361B2 (en) | 2000-05-04 | 2016-08-16 | Sarepta Therapeutics, Inc. | Splice-region antisense composition and method |
US10533174B2 (en) | 2000-05-04 | 2020-01-14 | Sarepta Therapeutics, Inc. | Splice-region antisense composition and method |
US8895722B2 (en) | 2000-05-04 | 2014-11-25 | Sarepta Therapeutics, Inc. | Splice-region antisense composition and method |
US8436163B2 (en) | 2000-05-04 | 2013-05-07 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
WO2002004479A1 (en) | 2000-07-06 | 2002-01-17 | Avi Biopharma, Inc. | TRANSFORMING GROWTH FACTOR BETA (TGF-β) BLOCKING AGENT-TREATED STEM CELL COMPOSITION AND METHOD |
EP3020804A1 (en) | 2000-07-06 | 2016-05-18 | Sarepta Therapeutics, Inc. | Transforming growth factor beta (tgf- ) blocking agent-treated stem cell composition and method |
US7973015B2 (en) | 2000-09-21 | 2011-07-05 | Academisch Ziekenhuis Leiden | Induction of exon skipping in eukaryotic cells |
EP2316951A1 (en) | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
US7045350B2 (en) | 2001-08-30 | 2006-05-16 | Mount Sinai School Of Medicine Of New York University | Alternatively spliced circulating tissue factor |
US8084015B2 (en) | 2002-02-14 | 2011-12-27 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US7208467B2 (en) | 2002-06-07 | 2007-04-24 | Monty Krieger | Lipid-altering compositions for the treatment of infertility |
US10100304B2 (en) | 2003-03-21 | 2018-10-16 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure |
US11208657B2 (en) | 2003-03-21 | 2021-12-28 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure |
US9896687B2 (en) | 2003-03-21 | 2018-02-20 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure |
US10544416B2 (en) | 2003-03-21 | 2020-01-28 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure |
US10113165B2 (en) | 2003-03-21 | 2018-10-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure |
US10190116B2 (en) | 2003-03-21 | 2019-01-29 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure |
US8580844B2 (en) | 2003-04-01 | 2013-11-12 | Georgia Regents Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US8232313B2 (en) | 2003-04-01 | 2012-07-31 | Georgia Health Sciences University | Pharmaceutical compositions containing 1-methyl-D-tryptophan |
US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
US9463239B2 (en) | 2003-04-01 | 2016-10-11 | Augusta University Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
WO2005017148A1 (en) | 2003-07-26 | 2005-02-24 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7928216B2 (en) | 2004-04-29 | 2011-04-19 | Yale University | Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases |
US8314072B2 (en) | 2004-07-02 | 2012-11-20 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
EP2351839A2 (en) | 2004-07-02 | 2011-08-03 | AVI BioPharma, Inc. | Antisense antibacterial method and compound |
US9534220B2 (en) | 2004-07-02 | 2017-01-03 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
US10626396B2 (en) | 2005-02-09 | 2020-04-21 | Sarepta Therapeutics, Inc. | Antisense composition and method for treating muscle atrophy |
US9499583B2 (en) | 2005-07-13 | 2016-11-22 | Sarepta Therapeutics, Inc. | Antibacterial antisense oligonucleotide and method |
US10144762B2 (en) | 2005-07-13 | 2018-12-04 | Sarepta Therapeutics, Inc. | Antibacterial antisense oligonucleotide and method |
US9249243B2 (en) | 2005-07-13 | 2016-02-02 | Sarepta Therapeutics, Inc. | Antibacterial antisense oligonucleotide and method |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US8536147B2 (en) | 2005-07-13 | 2013-09-17 | Sarepta Therapeutics, Inc. | Antibacterial antisense oligonucleotide and method |
US11395846B2 (en) | 2005-08-30 | 2022-07-26 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US9017679B2 (en) | 2005-08-30 | 2015-04-28 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US9839670B2 (en) | 2005-08-30 | 2017-12-12 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
US8304398B2 (en) | 2006-04-20 | 2012-11-06 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly or abnormally expressed gene |
US9045754B2 (en) | 2006-05-05 | 2015-06-02 | Isis Pharmaceuticals, Inc. | Short antisense compounds with gapmer configuration |
EP2735568A1 (en) | 2006-05-10 | 2014-05-28 | AVI BioPharma, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
US8361979B2 (en) | 2006-05-19 | 2013-01-29 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
US9890379B2 (en) | 2006-08-11 | 2018-02-13 | Biomarin Technologies B.V. | Treatment of genetic disorders associated with DNA repeat instability |
US10689646B2 (en) | 2006-08-11 | 2020-06-23 | Biomarin Technologies B.V. | Treatment of genetic disorders associated with DNA repeat instability |
US11274299B2 (en) | 2006-08-11 | 2022-03-15 | Vico Therapeutics B.V. | Methods and means for treating DNA repeat instability associated genetic disorders |
US8268962B2 (en) | 2007-07-12 | 2012-09-18 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
US9499818B2 (en) | 2007-10-26 | 2016-11-22 | BioMarin Technologies, B.V. | Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene |
US9926557B2 (en) | 2007-10-26 | 2018-03-27 | Biomarin Technologies B.V. | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
US10876114B2 (en) | 2007-10-26 | 2020-12-29 | Biomarin Technologies B.V. | Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53 |
US11427820B2 (en) | 2007-10-26 | 2022-08-30 | Biomarin Technologies B.V. | Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA |
US9243245B2 (en) | 2007-10-26 | 2016-01-26 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
US8263760B2 (en) | 2008-02-08 | 2012-09-11 | Prosensa Holding Bv | Methods and means for treating DNA repeat instability associated genetic disorders |
WO2009117553A2 (en) | 2008-03-20 | 2009-09-24 | University Of Florida Research Foundation, Inc. | Enhancing vessel lesion homing and repair potential of stem cells |
US9139828B2 (en) | 2008-05-14 | 2015-09-22 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means |
US10246707B2 (en) | 2008-05-14 | 2019-04-02 | Biomarin Technologies B.V. | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means |
WO2010062697A2 (en) | 2008-10-30 | 2010-06-03 | Peixuan Guo | Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses |
US11034956B2 (en) | 2009-04-24 | 2021-06-15 | Biomarin Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
US11634714B2 (en) | 2009-04-24 | 2023-04-25 | Biomarin Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
US10533171B2 (en) | 2009-04-24 | 2020-01-14 | Biomarin Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
US9499627B2 (en) | 2009-08-03 | 2016-11-22 | University Of Miami | Method for in vivo expansion of T regulatory cells |
US10934364B2 (en) | 2009-08-03 | 2021-03-02 | University Of Miami | Method for in vivo expansion of T regulatory cells |
US8697858B2 (en) | 2009-11-13 | 2014-04-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US9394323B2 (en) | 2009-11-13 | 2016-07-19 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
EP3199634A1 (en) | 2009-11-13 | 2017-08-02 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
WO2011060320A1 (en) | 2009-11-13 | 2011-05-19 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
WO2011113015A2 (en) | 2010-03-12 | 2011-09-15 | Avi Biopharma, Inc. | Antisense modulation of nuclear hormone receptors |
EP3023496A2 (en) | 2010-05-13 | 2016-05-25 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
US8779128B2 (en) | 2010-05-28 | 2014-07-15 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
US10760078B2 (en) | 2010-05-28 | 2020-09-01 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
WO2011150408A2 (en) | 2010-05-28 | 2011-12-01 | Avi Biopharma, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
US10202602B2 (en) | 2010-05-28 | 2019-02-12 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
US9469664B2 (en) | 2010-05-28 | 2016-10-18 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
EP3205342A1 (en) | 2010-08-09 | 2017-08-16 | Sarepta Therapeutics, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
WO2012021141A1 (en) | 2010-08-09 | 2012-02-16 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US11072793B2 (en) | 2010-09-03 | 2021-07-27 | Sarepta Therapeutics, Inc. | DsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
EP3067420A1 (en) | 2010-11-12 | 2016-09-14 | Sarepta Therapeutics, Inc. | Antisense antibacterial compounds and methods |
WO2012064991A1 (en) | 2010-11-12 | 2012-05-18 | Avi Biopharma, Inc. | Antisense antibacterial compounds and methods |
WO2012150960A1 (en) | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
US10100305B2 (en) | 2011-07-15 | 2018-10-16 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites |
WO2013012752A2 (en) | 2011-07-15 | 2013-01-24 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
US10421969B2 (en) | 2011-10-04 | 2019-09-24 | Royal Holloway And Bedford New College | Oligomers |
US10947536B2 (en) | 2011-10-04 | 2021-03-16 | Royal Holloway And Bedford New College | Oligomers |
US10662431B2 (en) | 2011-10-04 | 2020-05-26 | Royal Holloway And Bedford New College | Oligomers |
US11208655B2 (en) | 2011-11-18 | 2021-12-28 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
US9790499B2 (en) | 2011-11-18 | 2017-10-17 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
US10344281B2 (en) | 2011-11-18 | 2019-07-09 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
US9278987B2 (en) | 2011-11-18 | 2016-03-08 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
EP3858847A1 (en) | 2011-11-30 | 2021-08-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
WO2013082548A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
WO2013082551A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
WO2013086444A2 (en) | 2011-12-08 | 2013-06-13 | Sarepta Therapeutics, Inc. | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
US10913946B2 (en) | 2012-01-27 | 2021-02-09 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy |
US10179912B2 (en) | 2012-01-27 | 2019-01-15 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
EP3296320A1 (en) | 2012-03-08 | 2018-03-21 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2013134743A1 (en) | 2012-03-08 | 2013-09-12 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2013142087A1 (en) | 2012-03-20 | 2013-09-26 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
USRE48599E1 (en) | 2013-01-09 | 2021-06-22 | University Of Miami | Compositions comprising TLIA-Ig fusion protein for the regulation of T regulatory cells, and methods for their use |
US9603925B2 (en) | 2013-01-09 | 2017-03-28 | University Of Miami | Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use |
WO2014165814A1 (en) | 2013-04-04 | 2014-10-09 | Georgia State University Research Foundation, Inc. | Rna microchip detection using nanoparticle-assisted signal amplification |
WO2015035231A1 (en) | 2013-09-05 | 2015-03-12 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
WO2015038984A2 (en) | 2013-09-12 | 2015-03-19 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
US10767181B2 (en) | 2014-05-15 | 2020-09-08 | Hoffmann-La Roche Inc. | Oligomers and oligomer conjugates |
US11591598B2 (en) | 2014-05-15 | 2023-02-28 | Hoffmann-La Roche Inc. | Oligomers and oligomer conjugates |
US10421967B2 (en) | 2014-05-15 | 2019-09-24 | Hoffmann-La Roche Inc. | Oligomers and oligomer conjugates |
US11021706B2 (en) | 2014-05-16 | 2021-06-01 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
EP3620178A2 (en) | 2014-05-16 | 2020-03-11 | Oregon State University | Antisense antibacterial compounds and methods |
EP3569252A2 (en) | 2014-05-19 | 2019-11-20 | Oregon State University | Antisense antibacterial compounds and methods |
US10391098B2 (en) | 2014-05-19 | 2019-08-27 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
EP3626822A1 (en) | 2014-08-15 | 2020-03-25 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
US11293024B2 (en) | 2014-12-31 | 2022-04-05 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
US11015200B2 (en) | 2015-03-18 | 2021-05-25 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in myostatin |
WO2016196670A1 (en) | 2015-06-01 | 2016-12-08 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
US11911403B2 (en) | 2015-06-01 | 2024-02-27 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
EP3858993A1 (en) | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
WO2017112888A1 (en) | 2015-12-23 | 2017-06-29 | David Greenberg | Antisense antibacterial compounds and methods |
US10907158B2 (en) | 2015-12-23 | 2021-02-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
WO2017184529A1 (en) | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
US11060089B2 (en) | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
WO2017190041A1 (en) | 2016-04-29 | 2017-11-02 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
WO2021163079A1 (en) | 2020-02-10 | 2021-08-19 | Biomarin Pharmaceutical Inc. | Virus-free cell cultures |
WO2022269016A1 (en) | 2021-06-25 | 2022-12-29 | Stichting Radboud Universitair Medisch Centrum | Allele-specific silencing therapy for dfna21 using antisense oligonucleotides |
WO2023055774A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2024044770A1 (en) | 2022-08-26 | 2024-02-29 | Core Biotherapeutics, Inc. | Oligonucleotides for the treatment of breast cancer |
Also Published As
Publication number | Publication date |
---|---|
JPH07501204A (en) | 1995-02-09 |
WO1993001286A3 (en) | 1993-04-01 |
AU659482B2 (en) | 1995-05-18 |
AU2303292A (en) | 1993-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU659482B2 (en) | Localized oligonucleotide therapy | |
US5593974A (en) | Localized oligonucleotide therapy | |
WO1993008845A1 (en) | Localized oligonucleotide therapy | |
Shi et al. | Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. | |
EP0690726B1 (en) | Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells | |
US7235534B2 (en) | Antisense strategy to modulate estrogen receptor response (ER α and/or ER β ) | |
US5756476A (en) | Inhibition of cell proliferation using antisense oligonucleotides | |
CA2209989A1 (en) | Compositions and methods for treating tumor cells | |
EP0589330A2 (en) | NF-kappa beta antisense polynucleotides | |
EP0851919A1 (en) | Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate | |
JP4228111B2 (en) | Preventive and therapeutic agent for arteriosclerosis and vascular restenosis after PTCA surgery | |
WO2004092379A9 (en) | Method for treatment of angiogenic disorders | |
JP2002534117A (en) | Catalyst molecule | |
EP1071764B1 (en) | Antisense oligonucleotides for the inhibition of integrin alphav-subunit expression | |
HU219823B (en) | Oligonucleotides to inhibit the expression of isoprenyl protein transferases | |
US6110742A (en) | Synthetic antisense oligodeoxynucleotides targeted to AChE | |
WO1998007415A2 (en) | Methods for prevention of cellular proliferation and restenosis | |
JP2002509721A (en) | Methods and reagents for the treatment of diseases or conditions related to molecules involved in the angiogenic response | |
JP2003512442A (en) | Cancer Treatment | |
CA2228977A1 (en) | Localized oligonucleotide therapy for preventing restenosis | |
US20020151513A1 (en) | Localized oligonucleotide therapy for preventing restenosis | |
CA2152903A1 (en) | Antisense molecules directed against a fibroblast growth factor receptor gene family | |
US20030176384A1 (en) | Antisense oligonucleotides for the inhibition of integrin alphav -subunit expression | |
AU2003271376B8 (en) | Antisense Oligonucleotides for the Inhibition of Integrin alpha-Subunit Expression | |
MXPA00009974A (en) | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN&agr;v |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1992915263 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2082411 Country of ref document: CA |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: AU,CA EUROPEAN PATENT(AT,BE,DE,DK,FR,GB,IT,LU,MC,NL,SE) |
|
WWP | Wipo information: published in national office |
Ref document number: 1992915263 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992915263 Country of ref document: EP |